oral glp-1 drugs New Guidelines for Type 2 Diabetes in 2025 New GLP-1 Guidelines for Type
Description
Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time
GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy
No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc
The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c
Feel lighter and more in control of your life
A mechanistic guide to this next-generation metabolic peptide.
